Applied Genetic Technologies Co. (AGTC) Shares Sold by Millennium Management LLC

Millennium Management LLC lowered its stake in shares of Applied Genetic Technologies Co. (NASDAQ:AGTC) by 48.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 112,480 shares of the biotechnology company’s stock after selling 104,301 shares during the period. Millennium Management LLC’s holdings in Applied Genetic Technologies were worth $405,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Two Sigma Investments LP boosted its position in shares of Applied Genetic Technologies by 29.9% during the 4th quarter. Two Sigma Investments LP now owns 60,892 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 14,011 shares during the period. Spark Investment Management LLC boosted its position in shares of Applied Genetic Technologies by 122.1% during the 4th quarter. Spark Investment Management LLC now owns 107,700 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 59,200 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Applied Genetic Technologies by 48.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 394,490 shares of the biotechnology company’s stock worth $1,558,000 after purchasing an additional 128,049 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Applied Genetic Technologies by 32.5% during the 4th quarter. Renaissance Technologies LLC now owns 444,428 shares of the biotechnology company’s stock worth $1,600,000 after purchasing an additional 109,128 shares during the period. 45.86% of the stock is owned by hedge funds and other institutional investors.

Shares of Applied Genetic Technologies opened at $5.50 on Friday, MarketBeat reports. Applied Genetic Technologies Co. has a 52 week low of $5.30 and a 52 week high of $5.40.

Applied Genetic Technologies (NASDAQ:AGTC) last issued its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.04). Applied Genetic Technologies had a negative net margin of 65.96% and a negative return on equity of 16.00%. The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $6.41 million. analysts forecast that Applied Genetic Technologies Co. will post -1.38 EPS for the current fiscal year.

A number of research firms recently weighed in on AGTC. ValuEngine cut shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 8th. HC Wainwright set a $8.00 price objective on shares of Applied Genetic Technologies and gave the stock a “buy” rating in a research report on Wednesday, May 9th. Zacks Investment Research raised shares of Applied Genetic Technologies from a “sell” rating to a “hold” rating in a research report on Friday, March 30th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Applied Genetic Technologies in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Applied Genetic Technologies has an average rating of “Hold” and a consensus target price of $9.00.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Co. (NASDAQ:AGTC).

Institutional Ownership by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply